Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION

View through CrossRef
Objective: A stability-indicating high performance liquid chromatographic (HPLC) method was developed and validated for the estimation of combined tablet formulation of valsartan and sacubitril.Methods: Chromatographic separation was optimized by gradient HPLC on a C18 column [Xterra, 250 x 4.6 mm, 5µ] utilizing a mobile phase consisting acetonitrile, methanol and potassium dihydrogen phosphate, pH 3.8 in the ratio of 30: 50:20 v/v at a flow rate of 1 ml/min with UV detection at 263 nm.Results: The retention time of sacubitril and valsartan was 3.01 min and 4.22 min respectively. Good linearity obtained over the range of 20μg/ml to 160μg/ml for valsartan and sacubitril. The correlation coefficient was found to be 0.999and0.998 for sacubitril and valsartan respectively. The % RSD of precision for sacubitril and valsartan was found to be 0.31 and 0.27 respectively. The % mean recovery was found to be 99.20-99.54% for valsartan and 99.85-100.90% for sacubitril. The results obtained for accuracy, precision, LOD, LOQ and ruggedness were within limits.Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of valsartan and sacubitril in bulk and tablet dosage form. Thus the validated economical method was applied for forced degradation study of valsartan and sacubitril tablet.
Title: DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION
Description:
Objective: A stability-indicating high performance liquid chromatographic (HPLC) method was developed and validated for the estimation of combined tablet formulation of valsartan and sacubitril.
Methods: Chromatographic separation was optimized by gradient HPLC on a C18 column [Xterra, 250 x 4.
6 mm, 5µ] utilizing a mobile phase consisting acetonitrile, methanol and potassium dihydrogen phosphate, pH 3.
8 in the ratio of 30: 50:20 v/v at a flow rate of 1 ml/min with UV detection at 263 nm.
Results: The retention time of sacubitril and valsartan was 3.
01 min and 4.
22 min respectively.
Good linearity obtained over the range of 20μg/ml to 160μg/ml for valsartan and sacubitril.
The correlation coefficient was found to be 0.
999and0.
998 for sacubitril and valsartan respectively.
The % RSD of precision for sacubitril and valsartan was found to be 0.
31 and 0.
27 respectively.
The % mean recovery was found to be 99.
20-99.
54% for valsartan and 99.
85-100.
90% for sacubitril.
The results obtained for accuracy, precision, LOD, LOQ and ruggedness were within limits.
Conclusion: The proposed HPLC method was found to be simple, specific, precise, accurate, rapid and economical for simultaneous estimation of valsartan and sacubitril in bulk and tablet dosage form.
Thus the validated economical method was applied for forced degradation study of valsartan and sacubitril tablet.

Related Results

Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Abstract. Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morb...
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Abstract: Despite sacubitril/valsartan being on the market since 2015, clinicians are still determining the best way to initiate therapy to optimize outcomes and minimize...
A New Mechanism of Action in Heart Failure
A New Mechanism of Action in Heart Failure
Objective: To evaluate the efficacy, safety, and clinical significance of sacubitril/valsartan (Entresto) in patients with heart failure with a reduced ejection fraction (HFrEF). D...
Abstract 14627: Angiotensin-Neprilysin Inhibition in Cardiac Sarcoidosis
Abstract 14627: Angiotensin-Neprilysin Inhibition in Cardiac Sarcoidosis
Introduction: Sacubitril/Valsartan is an established treatment for heart failure patients with reduced ejection fraction (HFrEF). However, there is a paucity of data on...
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
AbstrakPendahuluan : Obstruksi ureter merupakan kondisi yang dapat terjadi pada setiap usia dengan levelbervariasi dengan efek terburuk berupa gagal ginjal permanen. Terdapat berba...
Sacubitil/valsartan in systemic right ventricular failure
Sacubitil/valsartan in systemic right ventricular failure
Abstract Background In patients with heart failure with low ejection fraction (EF) (≤35%) sacubitril/valsartan is proven to be b...

Back to Top